Renbioscience
1 employees on LinkedIn · 1 known investors
Find your way into Renbioscience
289 people in our graph share verified history with the Renbioscience team — schools, employers, funds. One of them is your warm intro.
Erin Mooreunlockedknows Ray Stevens · together at GSK (overlapped)
×4knows the team · via GSK
×2knows the team · via Andersen Consulting
×5knows the team · via University of Rhode Island
Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.
Founders & leadership
RS
Ray StevensinChief Executive OfficerRay Stevens is Chief Executive Officer of Ren BioScience, which develops small-molecule therapies for inherited retinal diseases, acute kidney injury, and mitochondrial-driven conditions. He has held leadership roles at GSK and multiple venture-backed biotechnology companies, with experience spanning drug discovery through regulatory readiness and also advises biotech CEOs and boards on development strategy.
DB
Dale BennyhoffinChief Operating OfficerDale Bennyhoff is Chief Operating Officer at Ren BioScience. He brings expertise in CMC, quality, and regulatory strategy across drug development, with a track record of supporting IND clearances and regulatory submissions for early- and mid-stage biotech programs.
DS
Dr. Stewart McCallumChief Medical Officer
Investors · 1
Competitors · 3
by search overlapDren Bio6 shared keywordsDren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
RenBio6 shared keywordsRenBio develops DNA-based therapeutic technology that uses intramuscular injection of therapeutic-encoding "bioblueprints" so a patient's own muscle cells produce antibodies and therapeutic proteins to prevent and treat diseases, including infectious diseases. The company works in the antibody and therapeutic protein field, aiming to overcome obstacles in delivery, durability, and cost.
NeoGenomics3 shared keywordsNeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.
Companies competing with Renbioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Renbioscience do?
- Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.
- Who are Renbioscience's investors?
- Renbioscience's investors include The Innovation Space.